Sep 2026· Hematology/Oncology Clinics of North America· 0 citations· 54 references
Medicine
TL;DR
Current evidence linking the microbiome-gut-brain axis to glioma development, progression, and treatment response is summarized, highlighting findings from human studies, preclinical models, and recent mechanistic investigations.
Abstract
Emerging evidence suggests that the gut microbiome contributes to glioma biology through immune regulation, microbial metabolites, and modulation of the tumor microenvironment. This review summarizes current evidence linking the microbiome-gut-brain axis to glioma development, progression, and treatment response, highlighting findings from human studies, preclinical models, and recent mechanistic investigations. The review also discusses the influence of the microbiome on anticancer therapy, current limitations of the field, and future directions for microbiome-based biomarkers and therapeutic strategies. Although clinical translation remains limited, microbial signals represent a promising area of investigation in neuro-oncology.
ABSTRACT Despite multimodal treatment, glioblastoma (GBM) remains difficult to control because of diffuse invasion, tumor heterogeneity, immune dysfunction, and frequent recurrence. Increasing attention has focused on whether intestinal microbial communities and their products can modify systemic and central nervous sy...
T. AlRamadneh, R. Jyothi S., Priya Priyadarshini-Nayak et al.· MicrobiologyOpen· 0 citations
A review of emerging interactions between OV treatment and the microbiome discusses how microbiome-informed strategies may complement OV-based immunotherapy and highlights the scarcity of longitudinal intratumoral and clinical microbiome data.
Farrukhbek Khamidov, Oybek Jalolov, Uktam Ne'matov et al.· Seminars in Oncology· 0 citations
Accumulating evidence supports the important role played by the gut microbiota in controlling anti-tumor immune responses that impact tumor development. Extensive studies of bacterial species known to impact tumor growth have identified metabolites, produced by either bacteria or the host, that may alter efficacy of ch...
Ximena Diaz-Olea, Amanda Ramer-Tait, Jonathan E. Cohen et al.· Trends in Microbiology· 0 citations
Colorectal cancer (CRC) is a major global health burden, and chemotherapy resistance remains a major challenge to effective treatment. Increasing evidence indicates that the gut microbiota may contribute to variability in chemotherapy response in CRC through microbial metabolism, tumor-cell adaptation, immune regulatio...
Yan Li, Fang-Rui Wang, Tao Li et al.· Frontiers in Oncology· 0 citations
Esophageal cancer (EC) is a highly prevalent and aggressive gastrointestinal malignancy. Late diagnosis and heterogeneous responses to chemoradiotherapy and immune checkpoint inhibitor (ICI) therapies severely challenge clinical management. Accumulating evidence suggests that gut microbiota dysbiosis influences esophag...
Yong-Hao Li, Lu Zhou, Rui-Xue Huang et al.· Frontiers in Microbiology· 0 citations
Immune checkpoint inhibitors (ICIs) have transformed the treatment of multiple malignancies, yet durable clinical responses remain limited to a subset of patients. Accumulating evidence identifies the gut microbiome as a regulator of antitumour immunity that can influence treatment efficacy and toxicity through microbi...
M. Biazzo, M. Soriani, Marianna Micallef et al.· Microorganisms· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
